Solid TumorADN-CONCT04496375
An Evaluation of Patients Access to Their Electronic Medical Records Via the IPC Connect Application
An observational study of Solid Tumor and Hematologic Malignancy, run by Institut Paoli-Calmettes.
Trial summary
The aim of our study is to investigate the effect of providing patients access to their electronic medical records Via the IPC Connect Application on their A Survey will be proposed to all outpatients with a solid or hematologic malignancy who will attend an appointement at Institut Paoli Calmettes clinic. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Solid Tumor, Hematologic Malignancy
- What is being tested?
- Survey
- How many people
- 8,000 participants
- Where
- No sites listed yet
- Study dates
- 5 Nov 2020to 5 Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All outpatients with an solid tumor or an hematologic malignancy who will attend Institut Paoli-Calmettes Outpatients clinic during 1 months
Who may be able to join
- Man or woman, age> 18 Years
- Solid tumor or hematologic malignancy
- Patient attending an appointment at Institut Paoli Calmettes
- Non-opposition
Who cannot join
- emergency, Vulnerable person or unable to provide informed consent
- First appointment at Institut Paoli Calmettes
Trial locations and contacts
No sites are listed yet.
About this study
The aim of our study is to investigate the effect of providing patients access to their electronic medical records Via the IPC Connect Application on their A Survey will be proposed to all outpatients with a solid or hematologic malignancy who will attend an appointement at Institut Paoli Calmettes clinic.
Data will be collected during a 1-month period. The auto-questionnaire will be composed of 31 questions addressed to all patients, 17 questions will be specifically addressed to patients using IPC connect application and 7 questions will be addressed to patients who do not use the application.
- Conditions
- Solid Tumor, Hematologic Malignancy
- Being tested
- Survey
- Keywords
- Electronic Medical Records, Patients anxiety
- Medical subject headings
- Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SurveyOther
Self-completed questionnaires
| Study group | Role | What they receive |
|---|---|---|
| Institut Paoli Calmettes Outpatients | Patients with a solid tumor or an hematologic malignancy who will attend an appointement at IPC Outpatients clinic Receives: Other: Survey |
What is being measured
The primary outcome is the main question the study is designed to answer.
Impact of Patients Access to Their Electronic Medical Records Via the IPC Connect Application on patients anxiety level
Anxiety level will be measured by the Hospital Anxiety and Depression scale
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2020
- Study start5 Nov 2020 (estimated)
- Primary completion5 Dec 2020 (estimated)
- Study completion5 Dec 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Solid TumorStudies of the same condition, open and under way.
- More trials run by Institut Paoli-CalmettesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 8,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut Paoli-Calmettes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Gwenaelle Gravis, Principal investigator, Institut Paoli-Calmettes
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04496375
- Sponsor's protocol ID
- ADN-CO-IPC 2020-004
- Acronym
- ADN-CO
- Status last verified
- Jul 2020
- First submitted
- 29 Jul 2020
- Last updated
- 3 Aug 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Evaluation of Patients Access to Their Electronic Medical Records Via the IPC Connect Application
- ClinicalTrials.gov ID
- NCT04496375
- Acronym / sponsor ID
- ADN-CO / ADN-CO-IPC 2020-004
- Conditions
- Solid Tumor, Hematologic Malignancy
- Keywords
- Electronic Medical Records, Patients anxiety
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 8,000 participants (estimated)
- Lead sponsor
- Institut Paoli-CalmettesUniversity, hospital or other
- Study start
- 5 Nov 2020 (estimated)
- Primary completion
- 5 Dec 2020 (estimated)
- Study completion
- 5 Dec 2020 (estimated)
- First posted
- 3 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of our study is to investigate the effect of providing patients access to their electronic medical records Via the IPC Connect Application on their A Survey will be proposed to all outpatients with a solid or hematologic malignancy who will attend an appointement at Institut Paoli Calmettes clinic.
Data will be collected during a 1-month period. The auto-questionnaire will be composed of 31 questions addressed to all patients, 17 questions will be specifically addressed to patients using IPC connect application and 7 questions will be addressed to patients who do not use the application.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Institut Paoli Calmettes Outpatients | – | Other: SurveyPatients with a solid tumor or an hematologic malignancy who will attend an appointement at IPC Outpatients clinic |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All outpatients with an solid tumor or an hematologic malignancy who will attend Institut Paoli-Calmettes Outpatients clinic during 1 months
Key inclusion criteria (4 listed)
- Man or woman, age> 18 Years
- Solid tumor or hematologic malignancy
- Patient attending an appointment at Institut Paoli Calmettes
- Non-opposition
Key exclusion criteria (2 listed)
- emergency, Vulnerable person or unable to provide informed consent
- First appointment at Institut Paoli Calmettes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SurveySelf-completed questionnaires | Other | Institut Paoli Calmettes Outpatients |
Primary outcome
Impact of Patients Access to Their Electronic Medical Records Via the IPC Connect Application on patients anxiety level
Time frame: 1 day
Anxiety level will be measured by the Hospital Anxiety and Depression scale
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2020.
- Individual participant dataSharing planned: No
Related trials for Solid Tumor
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
Active, not recruitingPhase 3
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Solid Tumors
RecruitingPhase 1
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies
RecruitingObservational study
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gwenaelle Gravis principal investigator
Institut Paoli-Calmettes
Questions about this trial
What is this clinical trial studying?
An observational study of Solid Tumor and Hematologic Malignancy, run by Institut Paoli-Calmettes.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Dominique Genre, MD (+33491223778, drci.up@ipc.unicancer.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Impact of Patients Access to Their Electronic Medical Records Via the IPC Connect Application on patients anxiety level (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2020.